Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for aderem plus
Your search for adorem-plus retrieved no results
Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib.
Mondielli G, Mougel G, Darriet F, Roche C, Querdray A, Lisbonis C, Appay R, Dufour H, Chinot O, Graillon T, Barlier A. Mondielli G, et al. Cancers (Basel). 2022 Sep 13;14(18):4448. doi: 10.3390/cancers14184448. Cancers (Basel). 2022. PMID: 36139608 Free PMC article.
Trametinib also strongly inhibited cell proliferation and induced AKT activation. Combined treatment with alpelisib plus trametinib reversed the AKT activation induced by trametinib and induced an additive inhibitory effect irrespective of the cell lines or tumor features. …
Trametinib also strongly inhibited cell proliferation and induced AKT activation. Combined treatment with alpelisib plus trametinib r …
Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state.
Hume DA, Underhill DM, Sweet MJ, Ozinsky AO, Liew FY, Aderem A. Hume DA, et al. BMC Immunol. 2001;2:11. doi: 10.1186/1471-2172-2-11. Epub 2001 Oct 12. BMC Immunol. 2001. PMID: 11686851 Free PMC article.
Transient expression of constitutively active forms of TLR4 or TLR2 plus TLR6 stimulated IL-12 promoter activity. The effect of LPS, a TLR4 agonist, was additive with that of TLR2/6 but not TLR4, whilst that of lipopeptide, a TLR2 agonist, was additive with TLR4 but not TL …
Transient expression of constitutively active forms of TLR4 or TLR2 plus TLR6 stimulated IL-12 promoter activity. The effect of LPS, …